SCHEMBL17311287

SCHEMBL17311287

C=CCOC(=O)c1cc2cc(NCc3cc(NC(=O)c4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)ccc3C)cnc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 10/20 0.54
▸ EGFR P00533 9/20 0.54
▸ ABL1 P00519 8/20 0.52
▸ PDGFRA P16234 2/20 0.52
▸ BCR P11274 2/20 0.52
▸ FGFR1 P11362 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ FLT3 P36888 1/20 0.52
▸ LRRK2 Q5S007 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ YES1 P07947 1/20 0.52
▸ LYN P07948 1/20 0.52
▸ HCK P08631 1/20 0.52
▸ SRC P12931 1/20 0.52
▸ FRK P42685 1/20 0.52
▸ KIT P10721 2/20 0.52
▸ DDR1 Q08345 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17311263 0.94 BRAF (0.57) BRAFEGFRABL1PDGFRABCR
SCHEMBL15859903 0.92 EGFR (0.60) BRAFEGFRABL1PDGFRABCR
SCHEMBL17311270 0.92 EGFR (0.55) BRAFEGFRABL1PDGFRABCR
SCHEMBL15859861 0.90 BRAF (0.60) BRAFEGFRABL1PDGFRABCR
SCHEMBL31060809 0.90 BRAF (0.59) BRAFEGFRABL1PDGFRABCR
SCHEMBL15859828 0.90 BRAF (0.59) BRAFEGFRABL1PDGFRABCR
SCHEMBL15859803 0.89 BRAF (0.59) BRAFEGFRABL1PDGFRABCR
SCHEMBL15859829 0.87 BRAF (0.57) BRAFEGFRABL1PDGFRABCR
SCHEMBL15859912 0.86 ABL1 (0.58) BRAFEGFRABL1PDGFRABCR
SCHEMBL17321178 0.86 ABL1 (0.54) BRAFEGFRABL1PDGFRABCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493455-B2 Azaindole derivatives as inhibitors of protein kinases ORIBASE PHARMA (FR) 2016-11-15 — — US disclosed
US-20150353540-A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES ORIBASE PHARMA (FR) 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353540-A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES MAP3K5, MAP3K3, MAP3K20 BRAF 65/4885EGFR 1624/4885ABL1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback